Oikos is the Greek word for house, or by metonymy the persons of a house. The purpose of this program is to meet the goal of providing financial. MOX Reports. Authors note Prior to publication, the author filed a formal written whistleblower complaint with the United States Securities and Exchange Commission SEC, including details from the article below. Investment summary catalysts for a decline to true zero. The key points I will make in this article are as follows Nymox management has consistently and repeatedly misled shareholders about its prospects in a material way and then dumped stock at inflated prices without making timely SEC disclosures. The Handbook Of Credit Risk Management Originating In The Mind' title='The Handbook Of Credit Risk Management Originating In The Mind' />The stock price then crashes. Following the ensuing fraud lawsuits, Canadian Nymox reincorporated in the Bahamas to limit disclosure and legal liability. Version 19 of the Handbook was published on 1 October 2017. For more information, please click History above. Putting Money in Motion How much do migrants pay for domestic transfers Shreyas Gopinath, Justin Oliver, Ajay Tannirkulam, Supriyo Bhattacharya, R. R. Kulkarni. Terry Anderson, Ph. D, Institute for Credible Leadership Development. Terry has studied and taught leadership at the undergraduate and graduate levels, and has. It then quickly resumed its promotional activities from the Bahamas. Nymox has a history of using anonymous offshore Panamanian financiers who then fail to disclose share ownership or their unregistered offshore dumping of stock. Unremedied material weakness in internal controls, a going concern warning and a highly problematic penny stock auditor of past stock promotions. Auditor Thayer ONeal is simply a renamed spin off from previous auditor who was dissolved by the PCAOB for gross audit deficiencies. Nymoxs legal counsel has recently been charged by the SEC with stock fraud, engaging in pump and dumps and market manipulation. He has a long history of such activities. Nymoxs banker has a long history of involvement with penny stock promotions and blatant SEC violations when raising money for microcaps. Significant history of their troubled clients going to zero after raising money from investors. Biomechanics Of The Musculoskeletal System Nigg Pdf. The doctor who was quoted in the recent bullish Nymox press release failed to disclose his direct funding from Nymox as well as ownership of shares. More details on repeated small purchases by new board member James Robinson. Nymox Pharma NASDAQ NYMX is a no brainer short which I expect to go to true zero. The company bears many striking similarities to Forcefield Energy NASDAQ FNRG which quickly collapsed by 9. Multiple parties behind Nymox have been behind other stock promotions which have declined by at least 9. Shares of Nymox Pharma had nearly doubled this year as a result of several grossly misleading press releases issued by the company. The shares are now up by nearly 1. Nymox has been around for over 3. In November of 2. NX 1. 20. 7 had failed both Phase 3 clinical trials it was in, sending its stock to as low as 3. However, Nymox management had in its possession the information that the trials had failed for as long as 6 1. During that time well after the drug had failed, Nymox management continued to put out bullish press releases while dumping millions in stock without making timely SEC disclosures of the sales. During this time, Nymox also raised millions more for the company by placing unregistered stock with an anonymous offshore Panamanian shell company. The Panamanian shell has never disclosed its ownership and has never disclosed its sales of stock. On the legal side, Nymox is represented by Zouvas Associates LLP. Luke Zouvas was previously a partner with Luis Carrillo in the firm Carrillo Huettel Zouvas, LLP. That firm imploded when Carrillo was charged by the SEC in a wide range of small cap pump and dump fraud schemes involving Canadian stock promoters and Bahamas based brokers. Note that Nasdaq listed Nymox was originally a Canadian company. In order to avoid legal scrutiny and liability, Nymox recently July 2. Bahamas. Zouvas himself can now be tied to numerous small cap pump and dump stock promotions and was just recently April 2. SEC for outright stock fraud using offshore companies, undisclosed ownershipand sales of stock, as well as false and misleading press releases issued by the company. Past Zouvas stock promotions which all imploded bear striking similarities to Nymox. Nymox has quarterly revenues of less than 5. The company has had unremedied material weaknesses in internal controls for over two years and has a going concern warning. Nymoxs auditor, Thayer ONeal was created as a direct spinoff of LL Bradford, when that firm was recently shut down by the PCAOB for multiple gross audit deficiencies. The new spin off auditor simply changed its name and picked up LL Bradfords troubled clients, all of which aside from Nymox have imploded to just pennies. Nymoxs banker is Chardan Capital markets. Chardan and its founders have a lengthy history of run ins with regulators, including cases of market manipulation, numerous imploded reverse merger frauds and charges of defrauding the Small Business Administration. Similar to Forcefield Energy , Nymox appears to have just 1 institutional holdings with the rest supposedly being scattered among small retail holders. Nymox has zero research coverage. Following my exposure of Forcefield, the share price plunged 6. The Chairman was then quickly arrested by the FBI for manipulating the worthless stock. After being halted, Forcefield quickly fell to zero. I believe that with Forcefield there were large holdings of stock being held by undisclosed offshore holders. These holders were well aware that the company was a sham and were the first to dump shares at any price as soon as I exposed the promotion. There was simply no value in the company and no bottom in the share price. In the last section below, I will also provide more information on recent share purchases by an 8. Hollywood film director James Robinson who was appointed to the board of Nymox in 2. Background. Over the past few years, I have exposed a wide variety of deeply troubled companies. I have highlighted these companies as attractive targets for short selling opportunities. Following exposure, many of these companies quickly plunged by 8. Examples of my targets which subsequently plunged by at least 8. Biolase NASDAQ BIOL, Clean. Tech Solutions NASDAQ CLNT, Cyt. Rx NASDAQ CYTR, Erickson Air. Crane NASDAQ EAC, Forcefield Energy Galena NASDAQ GALE, Sungy Mobile NASDAQ GOMO, Ignite Restaurant Group NASDAQ IRG, Neo. Node NASDAQ NEON, Neptune Technologies NASDAQ NEPT, Northwest Bio NASDAQ NWBO, Ohr Pharma NASDAQ OHRP, Regulus NASDAQ RGLS, Sun. Coke NYSE SXC and Tear. Lab NASDAQ TEAR, Tokai Pharma NASDAQ TKAI. These were the absolute homerun short trades. But in fact, I have also exposed dozens of others which also quickly fell by at least 5. This can be seen by looking at a list of my prior articles. While not the epic homeruns, I would also consider drops of 5. In my earlier career years, I spent nearly a decade as an investment banker for a major firm on Wall Street, with a primary focus on healthcare companies, biotechs in particular. I performed due diligence on more companies than I can count and helped successful biotechs raise billions of dollars. I learned quite a bit about what separates real biotechs from the wanna bes. It is now many years later, and I have parlayed that experience into investing for my own account. I continue to focus heavily on biotechs and as my regular readers know I often focus on short selling opportunities, betting on declines in the share prices of biotechs which have underlying problems. Examples of my past biotech exposs include Cyt. Rx, Galena, Ziopharm NASDAQ ZIOP, Revance Therapeutics NASDAQ RVNC, Regulus, Keryx Biopharm NASDAQ KERX, Ohr Pharma. Each of these stocks quickly fell by at least 6. And now I get to tout my most recent successful short prediction. About 2 weeks ago, Shares of Tokai Pharma plunged by 8. Galeterone failed Phase 3 trials. This is yet another stock which I had warned investors about in late 2. When I wrote about Tokai, the stock had been trading at around 1. I showed that Tokai was engaged in after the fact cherry picking of data and highlighted heavy insider selling. I described Tokai as a no brainer short. Following my article, Tokais share price ground down to around 5. Failure of its drug was all but guaranteed.